Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing 闯翱罢搁翱尝鈩�, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company's stock maintained an average closing price of at least $1.00 for 13 consecutive trading days from June 18 to July 8, 2025.
The compliance confirmation was received on July 9, 2025, from Nasdaq's Listing Qualifications Department, effectively resolving the previous listing concern. Jupiter's shares are now fully compliant with Rule 5550(a)(2), and Nasdaq has closed the matter.
Jupiter Neurosciences (NASDAQ: JUNS), una societ脿 farmaceutica in fase clinica che sta sviluppando 闯翱罢搁翱尝鈩�, ha riconquistato con successo la conformit脿 al requisito minimo del prezzo di offerta di Nasdaq. Il titolo della societ脿 ha mantenuto un prezzo di chiusura medio di almeno 1,00 $ per 13 giorni di borsa consecutivi dal 18 giugno all'8 luglio 2025.
La conferma della conformit脿 猫 stata ricevuta il 9 luglio 2025 dal Dipartimento di Qualificazione delle Quotazioni di Nasdaq, risolvendo efficacemente la precedente problematica di quotazione. Le azioni di Jupiter sono ora pienamente conformi alla Regola 5550(a)(2) e Nasdaq ha chiuso la questione.
Jupiter Neurosciences (NASDAQ: JUNS), una empresa farmac茅utica en fase cl铆nica que desarrolla 闯翱罢搁翱尝鈩�, ha recuperado con 茅xito el cumplimiento del requisito m铆nimo del precio de oferta de Nasdaq. Las acciones de la compa帽铆a mantuvieron un precio de cierre promedio de al menos $1.00 durante 13 d铆as h谩biles consecutivos desde el 18 de junio hasta el 8 de julio de 2025.
La confirmaci贸n de cumplimiento se recibi贸 el 9 de julio de 2025 del Departamento de Calificaciones de Listado de Nasdaq, resolviendo efectivamente la preocupaci贸n previa sobre la cotizaci贸n. Las acciones de Jupiter ahora cumplen plenamente con la Regla 5550(a)(2), y Nasdaq ha cerrado el asunto.
Jupiter Neurosciences (NASDAQ: JUNS)電� 鞛勳儊 雼硠 鞝滌暯 須岇偓搿� 闯翱罢搁翱尝鈩㈧潉 臧滊皽 欷戩澊氅�, Nasdaq鞚� 斓滌唽 鞛呾鞍 臧�瓴� 鞖旉贝鞚� 靹标车鞝侅溂搿� 於╈”頃橃榾鞀惦媹雼�. 須岇偓 欤检嫕鞚� 2025雲� 6鞗� 18鞚茧秬韯� 7鞗� 8鞚缄箤歆� 13瓯半灅鞚� 鞐办啀鞙茧 韽夑窢 膦呹皜臧� 斓滌唽 $1.00 鞚挫儊鞚� 鞙犾頄堨姷雼堧嫟.
2025雲� 7鞗� 9鞚� Nasdaq 靸侅灔 鞛愱博 攵�靹滊攵�韯� 欷�靾� 頇曥澑鞚� 氚涭晿鞙茧┌, 鞚挫爠 靸侅灔 氍胳牅毳� 須臣鞝侅溂搿� 頃搓舶頃橃榾鞀惦媹雼�. Jupiter鞚� 欤检嫕鞚� 鞚挫牅 攴滌箼 5550(a)(2)鞚� 鞕勳爠頌� 欷�靾橅晿氅� Nasdaq電� 鞚� 氍胳牅毳� 膦呺頄堨姷雼堧嫟.
Jupiter Neurosciences (NASDAQ : JUNS), une entreprise pharmaceutique en phase clinique d茅veloppant 闯翱罢搁翱尝鈩�, a r茅ussi 脿 retrouver la conformit茅 avec l'exigence minimale du prix de l'offre de Nasdaq. L'action de la soci茅t茅 a maintenu un prix de cl么ture moyen d'au moins 1,00 $ pendant 13 jours de bourse cons茅cutifs, du 18 juin au 8 juillet 2025.
La confirmation de conformit茅 a 茅t茅 re莽ue le 9 juillet 2025 du d茅partement des qualifications de cotation de Nasdaq, r茅solvant ainsi efficacement la pr茅occupation pr茅c茅dente concernant la cotation. Les actions de Jupiter sont d茅sormais pleinement conformes 脿 la r猫gle 5550(a)(2), et Nasdaq a clos le dossier.
Jupiter Neurosciences (NASDAQ: JUNS), ein Pharmaunternehmen in der klinischen Entwicklungsphase, das 闯翱罢搁翱尝鈩� entwickelt, hat erfolgreich die Einhaltung der Mindestgebotspreisanforderung von Nasdaq wiedererlangt. Die Aktien des Unternehmens hielten vom 18. Juni bis zum 8. Juli 2025 f眉r 13 aufeinanderfolgende Handelstage einen durchschnittlichen Schlusskurs von mindestens 1,00 $.
Die Best盲tigung der Einhaltung wurde am 9. Juli 2025 von der Abteilung f眉r Listing-Qualifikationen bei Nasdaq erhalten, womit die vorherige Listing-Angelegenheit effektiv gel枚st wurde. Die Aktien von Jupiter erf眉llen nun vollst盲ndig die Regel 5550(a)(2), und Nasdaq hat die Angelegenheit abgeschlossen.
- Successfully regained Nasdaq listing compliance, removing delisting risk
- Stock price showed positive upward trend, maintaining $1.00 minimum for 13 consecutive days
- Maintained Nasdaq listing status without requiring reverse stock split
- Previous trading below $1.00 indicates recent financial challenges
- Compliance achievement doesn't address underlying business fundamentals
Nasdaq compliance follows positive upward trend in Company鈥檚 Stock Price聽
Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (鈥淛upiter鈥� or the 鈥淐ompany鈥�), a clinical-stage pharmaceutical company developing JOTROL鈩�, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market (鈥淣asdaq鈥�) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company鈥檚 Current Report on Form 8-K filed on July 10, 2025.
On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company鈥檚 common stock has maintained an average closing share price of at least
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia鈩⒙�product line. Both efforts are powered by JOTROL鈩�, Jupiter鈥檚 proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company鈥檚 prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson鈥檚 disease, includeing indications such as Alzheimer鈥檚 Disease, Mucopolysaccharidoses Type I, Friedreich鈥檚 Ataxia, and MELAS. More information may be found on the Company鈥檚 website聽.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company鈥檚 current expectations, including the Company鈥檚 ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 鈥渁pproximates,鈥� 鈥渂elieves,鈥� 鈥渉opes,鈥� 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渆stimates,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� 鈥渟hould,鈥� 鈥渃ould,鈥� 鈥渕ay鈥� or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company鈥檚 final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company鈥檚 securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
FAQ
When did Jupiter Neurosciences (JUNS) regain Nasdaq compliance?
What is Jupiter Neurosciences' main product in development?
What was the minimum share price requirement for JUNS to maintain Nasdaq listing?
How long did JUNS need to maintain the minimum share price to regain compliance?
What type of company is Jupiter Neurosciences (JUNS)?
